Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

NCT05477693 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: Experimental 23-valent PPV
BIOLOGICAL: Control 23-valent PPV

Sponsor

Sinovac Biotech Co., Ltd